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Significant levels of IgG3 and IgG4 and high levels of IgG1 leishmania-specific antibody differentiated the immune states in 10 patients with visceral leishmaniasis from those of virtually all 20 drug-cured and 18 subclinically infected subjects, whereas the level of IgG2
antibody was nondiscriminating. The most extreme "subclinically infected" outlier subsequently developed disease. Overall, the immune states in subclinically infected and drug-cured persons were mutually indistinguishable but were readily distinguished from those of patients. These findings may have implications for the immunologic mechanism underlying drug cure in visceral leishmaniasis.
Infection by Leishmania donovani can lead to progressive and, unless treated, fatal visceral disease or to a relatively benign state. Progressive infection is associated with poor delayed-type hypersensitivity (DTH) and high antibody production, whereas containment is associated with a strong cell-mediated DTH response [1] . The immune response of patients probably has a Th2 component, whereas interferon-g-producing parasite-specific T cells exist in subclinically infected persons [2, 3] . Antiparasite drug treatment is effective but has significant toxicity and morbidity. Treatment results in decreased antibody and increased DTH to leishmanial antigens [1, 4, 5] .
Most murine models of therapy for cutaneous leishmaniasis Received are effective only when treatment is administered near the time of infection (e.g. [6] ). A reason for studying human visceral leishmaniasis is that drug treatment of patients with established disease results in cure and often in resistance to reinfection, suggesting redirection of polarized responses to the host's benefit. Understanding the basis of such redirection may lead to improved strategies for treating disease.
The importance of the Th1/Th2 nature of the immune response in determining the pathophysiologic outcome of infections has become more apparent in animal models of human infectious diseases. However, determination of the Th1/Th2 nature of human immune responses is often problematic. The relative abundance of different subclasses of pathogen-specific antibody in mice provides a good indication of the Th1/Th2 nature of the systemic response [7] . Therefore, we attempted to discriminate among the immunity of patients, healthy contacts, and drug-cured persons by assessing the relative abundance of IgG subclasses of antiparasite antibodies. Such discrimination is essential for the rational design of strategies for vaccination and treatment.
Subjects and Methods
Study subjects. This study was conducted in Aba Roba, 600 km southwest of Addis Ababa, Ethiopia, where visceral, but not cutaneous or mucocutaneous leishmaniasis, is endemic. Prevalence of human immunodeficiency virus infection is !0.1%. Serum samples were collected from 58 persons and were stored at Ϫ70ЊC. Ten persons had visceral leishmaniasis, 18 had subclinical infections, and 20 had been successfully treated 1-9 years earlier with sodium stibogluconate (Pentostam; Glaxo-Wellcome; 20 mg/kg/day for 20 days). Ten healthy control subjects from the endemic area were included. Visceral leishmaniasis was diagnosed on the basis of prolonged fever, weight loss, splenomegaly, and pancytopenia; positivity by direct agglutination test (DAT) for antibody to parasites [8] ; and the presence of parasites in the lymph node or splenic aspirates, as assessed by using direct smear or culture. Persons with subclinical infections were determined to be seropositive by DAT. Eleven of these 18 persons were asymptomatic, 5 had palpable spleens, and 2 had palpable livers. Serum samples from treated persons obtained 1-9 years after treatment were tested for antibody by DAT.
Leishmanin skin test. Leishmanin (gift of M. Gramiccia, Istituto Superiore di Sanita, Rome) was prepared from L. infantum ZLON49. Each dose contained 0.1 mL of a lysate derived from pro- 5 5 ϫ 10 mastigotes and was administered intradermally into the volar surface of the arm. The reaction was read 48-72 h later.
Antigen preparation and ELISA for IgG subclasses. L. donovani parasites were grown in a 1:1 mixture of RPMI and M199 with 20% fetal calf serum (Gibco), and sonicated antigen was prepared from stationary phase promastigotes, as described elsewhere [9] . ELISAs were done with mouse anti-human IgG1, IgG2, IgG3, or IgG4 antibodies (Sigma Chemical), as described elsewhere [9] .
Results
We examined the L. donovani-specific IgG subclasses in 4 different groups: patients, persons with subclinical infections, persons successfully treated with Pentostam 1-9 years earlier, and healthy seronegative control subjects. Cured subjects were typed as seropositive or seronegative by DAT. Table 1 shows our findings. Patients had significantly higher titers of IgG1 antibodies than most persons in the other groups, with some overlap at a titer of 810 (3 patients and 2 healthy contacts). The 1 healthy contact outlier, with a titer of 21,870, subsequently developed disease and therefore was excluded from the subclinical group in statistical analyses. All treated persons had titers !810. However, treated persons had significantly higher levels of IgG1 antibody than did healthy control subjects (
). Both IgG3 and IgG4 antibodies were higher P ! .001 in most patients than in healthy contacts or treated persons. IgG2 titers did not differ significantly by group.
The various parameters were tested for evidence of intergroup differences by use of the Kruskal-Wallis nonparametric analysis of variance [10] . Highly significant differences were observed for IgG1 ( ), IgG3 ( ), IgG4 ( ), and skin sen-P ! .001 P ! .001 P ! .001 sitivity. When significant differences were found, we used Bonferroni corrected Mann-Whitney U tests [10] to determine the precise nature of the differences (see table 2 for P values). For IgG1, IgG3, IgG4, and skin sensitivity, the patient groups were different from healthy contacts and treated subjects-with higher antibody levels and lower skin sensitivity. The values of these 4 variables did not differ among healthy contacts and seropositive and seronegative drug-cured subjects. DAT levels differed be-tween patients and treated persons, but the patients' values of DAT narrowly missed significance when compared with those in healthy contacts.
To gain an integrated understanding of the nature of group differences, we did a Canonical variate analysis [11] by using information from all parameters (excluding DAT, as this parameter was involved in definition of groups) to describe the relationship among study groups. One significant ( ) P ! .0025 Canonical variate axis was obtained and accounted for 94.4% of the intergroup differences. High scoring on this axis corresponded to low skin sensitivity and high IgG1, IgG3, and IgG4 antibodies, representing patients; low scoring corresponded to high skin sensitivity and low antibodies, representing healthy contacts and treated persons.
The fraction of subjects who were positive for different antibody subclasses was determined at a serum dilution of 1:30 (table 3) . The presence of IgG3 and IgG4 was most diagnostic for active disease.
Discussion
Our observations confirm that the prevalence of different subclasses of antibody changes during drug treatment [12] and that the immune state between patients and healthy contacts differs [3] . Our study examined the immune state in patients, healthy contacts, and treated persons. Our major finding was that persons successfully treated with drugs have an immune state indistinguishable from that of healthy contacts, which is distinct from that of persons undergoing treatment. Thus, the results of this study, in the context of others [2, 3] , suggest that the response after drug treatment is modulated from a Th2 or mixed Th1/Th2 antiparasitic response towards the Th1 pole. The most extreme outlier, a subject originally designated as a subclinically infected contact, had developed disease when examined 6 months later, suggesting that a high level of IgG1 antibody may be useful as a prognostic marker for progression from a subclinical state to active visceral disease.
Some persons with subclinical infections were skin test negative but seropositive. Most probably they had a small cell-mediated response, undetectable by the skin test, since their antibodies were similar to those of skin test-positive subjects. However, 2 of the 3 subclinically infected subjects with the highest IgG1 levels had significant IgG4 antibody titers and a negative skin test. In this case, the lack of skin test positivity may reflect a significant Th2 component to the response that adversely affects skin test sensitivity [13, 14] .
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Values for IgG subclasses are shown as the reciprocal of the highest serum dilution above cutoff values. Cutoff values were determined by taking the average optical SD of the 10 healthy control subjects from the endemic area. density ϩ 2 DAT titers are expressed in simple decimals, from Ϫ1 to 11. Titers begin at 100 (expressed as 0) and end at 102,400 (expressed as 10). Cutoff titer for DAT assay is 400. All healthy control subjects had DAT titers below cutoff value. For LST, values 15 mm are considered to be positive. NA, results not available; UD, undetectable (values below cutoff). a Duration of illness (in months) at presentation. b Months between completion of treatment and serum collection. x P ! .001 x cells and production of associated antibodies [7] . Spleen cells, obtained from a mouse immunized to produce antibody but to express little DTH, evolve most efficiently to express potent DTH but produce little antibody when cultured in the presence of relatively low amounts of antigen [15] . On this basis, we suggest that ongoing mixed Th1/Th2 responses can be "reset" toward an exclusive, cell-mediated Th1 response if the response is sustained in the presence of a diminished amount of antigen to "reset" it. A recent report supports this concept. Treatment of visceral leishmaniasis with antimonial drugs was effective in most patients; the response was modulated, and parasite burden was dramatically decreased. In a few patients, neither the response nor the parasite burden was affected. The parasites were found to be drug resistant; treatment with a second-line drug resulted in cure and a modulation of the immune response [12] . Thus, drug effectiveness against the parasite is essential for the immune modulation observed. In our study, none of the 20 treated subjects experienced relapse, although they continued to live in the endemic area; however, such findings are not universal [16] . Perhaps the type of antibodies present after drug treatment may be used to predict relapses and to indicate the advisability of further treatment. It will be of interest to see whether our findings can be generalized in different geographic areas and in different ethnic groups.
